Tags

Type your tag names separated by a space and hit enter

Role of endocannabinoid signaling in anxiety and depression.
Curr Top Behav Neurosci. 2009; 1:347-71.CT

Abstract

Cannabinoid receptors and their endogenous ligands are located throughout the limbic, or "emotional," brain, where they modulate synaptic neurotransmission. Converging preclinical and clinical data suggest a role for endogenous cannabinoid signaling in the modulation of anxiety and depression. Augmentation of endocannabinoid signaling (ECS) has anxiolytic effects, whereas blockade or genetic deletion of CB₁ receptors has anxiogenic properties. Augmentation of ECS also appears to have anti-depressant actions, and in some assays blockade and genetic deletion of CB₁ receptors produces depressive phenotypes. These data provide evidence that ECS serves in an anxiolytic, and possibly anti-depressant, role. These data suggest novel approaches to treatment of affective disorders which could include enhancement of endogenous cannabinoid signaling, and warrant cautious use of CB₁ receptor antagonists in patients with pre-existing affective disorders.

Authors+Show Affiliations

Department of Pharmacology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21104391

Citation

Patel, Sachin, and Cecilia J. Hillard. "Role of Endocannabinoid Signaling in Anxiety and Depression." Current Topics in Behavioral Neurosciences, vol. 1, 2009, pp. 347-71.
Patel S, Hillard CJ. Role of endocannabinoid signaling in anxiety and depression. Curr Top Behav Neurosci. 2009;1:347-71.
Patel, S., & Hillard, C. J. (2009). Role of endocannabinoid signaling in anxiety and depression. Current Topics in Behavioral Neurosciences, 1, 347-71. https://doi.org/10.1007/978-3-540-88955-7_14
Patel S, Hillard CJ. Role of Endocannabinoid Signaling in Anxiety and Depression. Curr Top Behav Neurosci. 2009;1:347-71. PubMed PMID: 21104391.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of endocannabinoid signaling in anxiety and depression. AU - Patel,Sachin, AU - Hillard,Cecilia J, PY - 2010/11/25/entrez PY - 2009/1/1/pubmed PY - 2011/1/5/medline SP - 347 EP - 71 JF - Current topics in behavioral neurosciences JO - Curr Top Behav Neurosci VL - 1 N2 - Cannabinoid receptors and their endogenous ligands are located throughout the limbic, or "emotional," brain, where they modulate synaptic neurotransmission. Converging preclinical and clinical data suggest a role for endogenous cannabinoid signaling in the modulation of anxiety and depression. Augmentation of endocannabinoid signaling (ECS) has anxiolytic effects, whereas blockade or genetic deletion of CB₁ receptors has anxiogenic properties. Augmentation of ECS also appears to have anti-depressant actions, and in some assays blockade and genetic deletion of CB₁ receptors produces depressive phenotypes. These data provide evidence that ECS serves in an anxiolytic, and possibly anti-depressant, role. These data suggest novel approaches to treatment of affective disorders which could include enhancement of endogenous cannabinoid signaling, and warrant cautious use of CB₁ receptor antagonists in patients with pre-existing affective disorders. SN - 1866-3370 UR - https://www.unboundmedicine.com/medline/citation/21104391/Role_of_endocannabinoid_signaling_in_anxiety_and_depression_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21104391/ DB - PRIME DP - Unbound Medicine ER -